Lamictal licensed for bipolar disorder

19 November 2010

Depressive episodes are one of the symptoms of bipolar disorder

Lamictal (lamotrigine) has had its licence extended to include the treatment of bipolar disorder. Both the tablets and the orodispersible tablets may be used in the prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes.

The exact mechanism of action of lamotrigine in bipolar disease is unknown, but the anticonvulsant’s interaction with voltage-gated sodium channels is thought to be important.

View Lamictal drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...